Search results
Results from the WOW.Com Content Network
Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations and sending the stock up about 1% in premarket trading. Pfizer reported ...
Pfizer (NYSE: PFE) is an interesting healthcare company with excellent prospects for cash flow growth. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.
Pharmaceutical giant Pfizer (NYSE: PFE) is trading near its lowest price in over a decade. The company's revenue and profits ballooned during the pandemic on its COVID-19 vaccine and treatment.
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
PFE data by YCharts. More importantly, revenue and earnings bottomed and began rising again this year. This isn't a fluke; through nine months of 2024, Pfizer's specialty care products are up 11% ...
Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Pfizer beat on earnings in the first quarter of 2024, giving its stock a much-needed 7% boost Wednesday.The company reported $14.9 billion in revenue, down 19% compared to last year. That beat ...